Cool_老虎社区_美港股上老虎

OneZeroKing
2021-11-24

Cool

Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能会加入一个罕见的俱乐部，收入超过 100B 美元</blockquote>

Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n

Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能会加入一个罕见的俱乐部，收入超过 100B 美元</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":874990901,"tweetId":"874990901","gmtCreate":1637717625414,"gmtModify":1637717625414,"author":{"id":3582709148429690,"idStr":"3582709148429690","authorId":3582709148429690,"authorIdStr":"3582709148429690","name":"OneZeroKing","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Cool&nbsp;</body></html>","htmlText":"<html><head></head><body>Cool&nbsp;</body></html>","text":"Cool","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/874990901","repostId":1156246084,"repostType":2,"repost":{"id":"1156246084","kind":"news","pubTimestamp":1637710539,"share":"https://www.laohunote.com/m/news/1156246084?lang=zh_CN&edition=full","pubTime":"2021-11-24 07:35","market":"us","language":"en","title":"Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能会加入一个罕见的俱乐部，收入超过 100B 美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1156246084","media":"Barrons","summary":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its n","content":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，在新冠肺炎疫苗和新型新冠肺炎抗病毒药丸销售的推动下，辉瑞明年的收入将超过1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于 2020 年的 419 亿美元和 FactSet 一致估计的 2021 年 807 亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师 Geoffrey Porges 博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年将销售价值 240 亿美元的 Covid-19 药丸，2023 年将销售价值 330 亿美元。他还将辉瑞公司 Covid-19 疫苗明年的销售额预估从之前的 230 亿美元提高到 300 亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂地跻身年收入超过 1000 亿美元的标普500公司之列，其中包括沃尔玛 (WMT)、亚马逊 (AMZN)、苹果 (APPL) 和 CVS Health (CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到 2022 年底，这将为公司留下一笔巨大的战争资金。Porges 预计，到 2022 年底，辉瑞的现金和有价证券余额将达到 595 亿美元，假设辉瑞出售其在葛兰素史克 (GSK) 明年剥离的消费者医疗保健业务中的权益，则为 761 亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>随着761亿美元在其公司口袋里烧了一个洞，辉瑞公司明年将有火力购买几乎任何它想要的东西。这可能会为投资者创造一个有趣的猜测游戏。它还可能使大型生物技术市场升温，特别是在人们猜测诺华 (NVS) 在出售了价值超过 200 亿美元的罗氏控股公司 (RHHBY) 股份后，也在寻求大笔收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，波吉斯将辉瑞股票的目标价从之前的 48 美元上调至 52 美元。他维持对该股的市场表现评级。辉瑞股价周一收于 51.20 美元，周二盘前交易中下跌 0.3%。今年迄今为止，该股已上涨 39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦他在一篇杂志特写中认为，辉瑞公司的 Covid-19 抗病毒药物的明显疗效表明，该公司在自己的科学上下的赌注是一个好的赌注，而且该股票是一项不错的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges 的估计远远超出了 FactSet 分析师的一致估计，辉瑞公司在 2022 年的收入为 815 亿美元，在 2023 年的收入为 660 亿美元。Porges 写道，他对这种名为 Paxlovid 的抗病毒药物销量的预测是基于 2005 年至 2007 年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>“默克公司和辉瑞公司已宣布在 2022 年分别向美国政府提供价值 22 亿美元（310 万个疗程）和 52.9 亿美元（1000 万个疗程）的抗病毒药物合同，我们预计未来几个月将签订更多合同。“前两份合同足以覆盖 2021 年迄今为止确诊的 46% 的 COVID 病例，如果进行储备，只能覆盖 4% 的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已经安排了一次咨询委员会听证会，以考虑在11月底授权默克(MRK)的新冠肺炎抗病毒药物。审议辉瑞公司抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能会加入一个罕见的俱乐部，收入超过 100B 美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能会加入一个罕见的俱乐部，收入超过 100B 美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBarrons2021-11-24 07:35\n\n</h4>\n</header>\n<article>\nPfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.<blockquote>据SVB Leerink称，在新冠肺炎疫苗和新型新冠肺炎抗病毒药丸销售的推动下，辉瑞明年的收入将超过1000亿美元。</blockquote> That’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.<blockquote>这高于 2020 年的 419 亿美元和 FactSet 一致估计的 2021 年 807 亿美元。</blockquote> Analyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects&nbsp;Pfizer&nbsp;(ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.<blockquote>分析师 Geoffrey Porges 博士在周二早些时候发布的一份报告中写道，他预计辉瑞（股票代码：PFE）明年将销售价值 240 亿美元的 Covid-19 药丸，2023 年将销售价值 330 亿美元。他还将辉瑞公司 Covid-19 疫苗明年的销售额预估从之前的 230 亿美元提高到 300 亿美元。</blockquote> That would briefly put Pfizer in the rarefied club of&nbsp;S&amp;P 500&nbsp;companies that clock more than $100 billion per year in revenue, including Walmart&nbsp;(WMT),Amazon&nbsp;(AMZN),Apple&nbsp;(APPL), and&nbsp;CVS Health&nbsp;(CVS).<blockquote>这将使辉瑞短暂地跻身年收入超过 1000 亿美元的标普500公司之列，其中包括沃尔玛 (WMT)、亚马逊 (AMZN)、苹果 (APPL) 和 CVS Health (CVS)。</blockquote> What’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that&nbsp;GlaxoSmithKline&nbsp;(GSK) is spinning out next year.<blockquote>更重要的是，到 2022 年底，这将为公司留下一笔巨大的战争资金。Porges 预计，到 2022 年底，辉瑞的现金和有价证券余额将达到 595 亿美元，假设辉瑞出售其在葛兰素史克 (GSK) 明年剥离的消费者医疗保健业务中的权益，则为 761 亿美元。</blockquote> With $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that&nbsp;Novartis&nbsp;(NVS) is also looking for a big-ticket purchase, after selling a stake in&nbsp;Roche Holding&nbsp;(RHHBY) worth more than $20 billion.<blockquote>随着761亿美元在其公司口袋里烧了一个洞，辉瑞公司明年将有火力购买几乎任何它想要的东西。这可能会为投资者创造一个有趣的猜测游戏。它还可能使大型生物技术市场升温，特别是在人们猜测诺华 (NVS) 在出售了价值超过 200 亿美元的罗氏控股公司 (RHHBY) 股份后，也在寻求大笔收购的情况下。</blockquote> In his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.<blockquote>在周二的报告中，波吉斯将辉瑞股票的目标价从之前的 48 美元上调至 52 美元。他维持对该股的市场表现评级。辉瑞股价周一收于 51.20 美元，周二盘前交易中下跌 0.3%。今年迄今为止，该股已上涨 39.1%。</blockquote> Earlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.<blockquote>本月早些时候，巴伦他在一篇杂志特写中认为，辉瑞公司的 Covid-19 抗病毒药物的明显疗效表明，该公司在自己的科学上下的赌注是一个好的赌注，而且该股票是一项不错的长期投资。</blockquote> Porges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.<blockquote>Porges 的估计远远超出了 FactSet 分析师的一致估计，辉瑞公司在 2022 年的收入为 815 亿美元，在 2023 年的收入为 660 亿美元。Porges 写道，他对这种名为 Paxlovid 的抗病毒药物销量的预测是基于 2005 年至 2007 年间流感抗病毒药物的历史库存。</blockquote> “Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”<blockquote>“默克公司和辉瑞公司已宣布在 2022 年分别向美国政府提供价值 22 亿美元（310 万个疗程）和 52.9 亿美元（1000 万个疗程）的抗病毒药物合同，我们预计未来几个月将签订更多合同。“前两份合同足以覆盖 2021 年迄今为止确诊的 46% 的 COVID 病例，如果进行储备，只能覆盖 4% 的美国人口。”</blockquote> The Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of&nbsp;Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.<blockquote>美国食品和药物管理局已经安排了一次咨询委员会听证会，以考虑在11月底授权默克(MRK)的新冠肺炎抗病毒药物。审议辉瑞公司抗病毒药物的会议尚未安排，但预计很快就会召开。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0\">Barrons</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/pfizer-stock-sales-covid-19-vaccine-pill-51637676691?mod=hp_DAY_0","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156246084","content_text":"Pfizer‘s revenue will top $100 billion next year, boosted by sales of its Covid-19 vaccine and its new Covid-19 antiviral pill, according to SVB Leerink.\nThat’s up from $41.9 billion in 2020, and the FactSet consensus estimate of $80.7 billion in 2021.\nAnalyst Dr. Geoffrey Porges wrote in a note out early Tuesday that he expects Pfizer (ticker: PFE) to sell $24 billion worth of its Covid-19 pill next year, and $33 billion in 2023. He also increased his estimate for sales of Pfizer’s Covid-19 vaccine next year to $30 billion, from his previous estimate of $23 billion.\nThat would briefly put Pfizer in the rarefied club of S&P 500 companies that clock more than $100 billion per year in revenue, including Walmart (WMT),Amazon (AMZN),Apple (APPL), and CVS Health (CVS).\nWhat’s more, it would leave the company with an enormous war chest by the end of 2022. Porges expects Pfizer to have a cash and marketable securities balance of $59.5 billion by the end of 2022—or $76.1 billion assuming it sells its interest in the consumer healthcare business that GlaxoSmithKline (GSK) is spinning out next year.\nWith $76.1 billion burning a hole in its corporate pocket, Pfizer would have the firepower to buy just about anything it wanted to next year. That could create an interesting guessing game for investors. It could also potentially heat up the large-cap biotech market, particularly amid speculation that Novartis (NVS) is also looking for a big-ticket purchase, after selling a stake in Roche Holding (RHHBY) worth more than $20 billion.\nIn his Tuesday note, Porges increased his target price on Pfizer stock to $52, from a previous $48. He maintained his Market Perform rating on the stock. Pfizer shares closed at $51.20 on Monday and were down 0.3% in premarket trading on Tuesday. The stock is up 39.1% so far this year.\nEarlier this month, Barron’sargued in a magazine feature that the apparent efficacy of Pfizer’s Covid-19 antiviral showed that the bet that the company had taken on its own science was a good one, and that the stock was a good long-term investment.\nPorges’ estimates are well beyond the FactSet analyst consensus estimates, which have Pfizer reporting $81.5 billion in revenues in 2022, and $66 billion in 2023. Porges wrote that his forecasts for sales of the antiviral, known as Paxlovid, are based on historical stockpiling of flu antivirals between 2005 and 2007.\n“Merck and Pfizer have announced contracts to supply their antivirals to the U.S. government worth $2.2bn (3.1mm courses) and $5.29bn (10mm courses), respectively for 2022, and we expect many more contracts in the coming months,” Porges wrote. “The first two contracts are sufficient for 46% of the cases of COVID that have been diagnosed so far in 2021, and if consigned to stockpiling, would cover only 4% of the U.S. population.”\nThe Food and Drug Administration has scheduled an advisory committee hearing to consider authorization of Merck‘s (MRK) Covid-19 antiviral at the end of November. A meeting to consider Pfizer’s antiviral hasn’t yet been scheduled, but is expected soon after.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":3699,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Pfizer Could Join a Rare Club Next Year With Revenue Above $100B<blockquote>辉瑞明年可能会加入一个罕见的俱乐部，收入超过 100B 美元</blockquote>

评论（1）

热议股票